On Assignment



On Assignment, Inc. 2014 Analyst Day

March 26, 2014

Updated on April 11, 2014 to include in an Appendix supplemental data on new reporting Segments and Adjusted Income from Continuing Operations, along with per share amounts



Safe Harbor



This presentation contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and involve a high degree of risk and uncertainty. Forward-looking statements include statements regarding the Company's anticipated future financial and operating performance. All statements in this presentation, other than those setting forth strictly historical information, are forward-looking statements. Forward-looking statements are not guarantees of future performance, and actual results might differ materially. In particular, the Company makes no assurances that estimates of revenues, gross margin, SG&A, Adjusted EBITDA, cash flow and other financial metrics will be achieved. Factors that could cause or contribute to such differences include actual demand for our services, our ability to attract, train and retain qualified staffing consultants, our ability to remain competitive in obtaining and retaining staffing clients, the availability of qualified temporary and permanent placement professionals, management of our growth, continued performance of our enterprise-wide information systems, and other risks detailed from time to time in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on March 3, 2014. We specifically disclaim any intention or duty to update any forward-looking statements contained in this presentation.


ASGN: A Decade of Growth

Peter Dameris Appointed CEO Implemented


Revitalization

Plan










NYSE Listing



Divested Nurse Travel

Divested Allied Healthcare



















\$373

\$516

\$1,138

\$1,632

2003-2005

2006 - 2009

2010

2011

2012


2013



Delivering Shareholder Value



Cumulative Total Return Summary





Compelling Results

- Generated 10 year revenue CAGR of 22.8%
- Proven ability to leverage and de-leverage
- Delivered industry leading margins and conversion rates
- Increased market cap from \$150 million to \$2.0 billion
- Maintained strong cash flow through economic cycles
- Executed strategic and accretive acquisitions

ASGN Is a Growth Story








\$3 Billon

Revenue



+100 to 200 bps

Adjusted EBITDA Margin

On Assignment Strategic Plan 2014 - 2018







Reviewed industry dynamics



Analyzed professional staffing market segments



Assessed market opportunity



Refined long-term vision and goals




Developed strategic objectives and growth plans



Staffing Industry Dynamics

U.S. Temp Penetration Rate 2011-2013




- For every 100 U.S. employees, there are 2 temp workers
- Current U.S. temp penetration rate is close to the historical peak in April 2000
- Temp penetration is expected to reach a new high in 2014
- U.S. still well below temp penetration rate in developed European economies
- Rate for computer and mathematical temporary occupations expanding rapidly



Staffing Industry Dynamics

GDP Is a Significant Predictor of Staffing Industry Growth

Staffing Industry Revenue Growth (Excl. PEO/Outplacement) as function of GDP growth






Staffing Industry Dynamics




Long-Term Shift from Commercial to Professional Staffing



- Increasing level of contract vs. permanent staffing
 - Relieves legislative burdens
 - Reduces costs
 - Provides flexibility, quality and control
- Continuing economic uncertainty



ASGN Operates in Dynamic Markets



Market Size 2013



Benefits of Size and Scale

- Ongoing threat of security breaches
- Clients demanding higher levels of insurance and contractual terms
- Vendor lists are being consolidated
- Large, established firms winning and smaller firms squeezed out



"I know that it is frustrating for our guests to learn that

this information was taken




On Assignment's Strategic Assessment



Category	Market	Market Attractiveness	ASGN's Position	Ability to Execute	Commentary
Currently Served Markets	IT Staffing				Largest marketSolid growthASGN's best competitive position
	Clinical/ Scientific				High growth marketHigh margins
	Engineering				Solid marginsFits well with "STEM"
	Physician (Locum Tenens)				Expect strong demandHigh average bill rate
Past Served Markets	Allied Healthcare				Extreme fragmentation of customer and competitorsSolid HIM business
	Nursing			N/A	 Large market, tough competitive dynamics
Adjacent Markets	Finance & Accounting		N/A		Large marketCompetitive structure (RHI) is tough
	Legal		N/A		 Small (\$1B) and lower growth = dilutive to portfolio



IT Staffing Market Size and Growth






IT Staffing Industry Dynamics

- On Assignment is 2nd largest U.S. IT staffing firm with 2013 revenues of \$1.3 billion
- Technology is increasingly embedded in business
- Development cycles are becoming shorter
- Current technical skills are becoming obsolete
- Shortages of new technical skills are becoming more acute
- Staffing industry as a disrupter
- Immigration reform and "political winds" driving trends toward onshore resources
- Most attractive IT deployment model


U.S. IT Staffing Revenue by Competitor, 2012



The CIO Perspective


Four IT Deployment Models

Expected Growth: 2013 and 2014



Clinical/Scientific Staffing Market Size and Growth








Clinical/Scientific Staffing Market Dynamics


- On Assignment is the 4th largest U.S. clinical/scientific staffing firm with 2013 revenues of \$172 million
- Highly fragmented; favorable market dynamics
- Mid-market, small/medium clients favor personalized service
- Clinical trials in progress tend to carry through the assignments
- Many VC-backed start-ups with the need for a flexible workforce

U.S. Clinical / Scientific Staffing Revenue by Competitor, 2012





Physician Staffing Market Size and Growth






Physician Staffing Market Dynamics

- On Assignment is the 4th largest U.S. physician staffing firm (post-Whitaker Medical acquisition) with 2013 revenues of \$106 million
- Expected shortage of up to 45,000
 primary care doctors in the U.S. by 2020 ²
- High Barriers to Entry: Insurance, complexity, specialization, licensing
- Physician Workforce Demographics: More part-time workers; increasing desire for flex-time
- Long-term growth expected to be fueled by physician shortage, aging population, more accessible healthcare insurance

U.S. Physician Staffing Revenue by Competitor, 2012 ¹





ASGN Market Opportunity

- Secular trends driving growth
- Diverse market segment characteristics
- Domestically focused
- Significant competitive advantages
- Positioned to capture market share:
 Size, Sophistication, Brand Awareness



On Assignment Vision





Strategic Planning Conclusions

- Specialize in large and growing professional staffing markets:
 Technology, Life Sciences and Healthcare
- Be a dominant competitor in each of these markets
- Refocus non-physician healthcare staffing expertise on business and technology opportunities and away from clinical skills
- Domestic markets provide significant growth opportunities over more fragmented and complex international markets
- Leverage fixed cost so revenue growth provides higher incremental adjusted EBITDA margin



Key Strategic Planning Actions

- Invest in domestic opportunities in the large and growing technology, life sciences and healthcare markets
- Exit Allied Healthcare due to small market size and our limited ability to become a dominant player
- 3. Grow our physician staffing business
- Pursue growth in permanent placement staffing
- Realign business units by business model to leverage our scale and expertise
- 6. Continue disciplined strategic acquisitions




On Assignment Business Models



High Skill, High Bill Rate Market

Market Characteristics

- Specialized skills
- Scarce talent; typically travels
- Direct buyer with urgent need
- Many small competitors



Business Model

- Recruiting-driven
- Served via long-line approach
- Quality/unique skill of candidate and speed of response most valued
- Fewer assignments per client
- Higher rates and gross margins

Market Characteristics

- More accessible skills
- Large and local talent pool
- Centralized buyer program
- More large and small competitors





Business Model

- Sales-driven
- Fortune 500 and local retail clients
- Served by local offices
- Relationship, speed, reliability, price most valued
- More assignments per client
- Lower rates and gross margins
- Scale matters. Requires highly efficient delivery system.

Mid-tier Skill, Volume Market



Before Organizational Realignment




Business units were aligned by skill specialty






After Organizational Realignment

- Divested On Assignment healthcare staffing
- Realigned business units by business model





New Divisional Reporting Structure





Major Benefits of Realignment



- ✓ Accelerate revenue growth in Lab Support, Valesta, and HIM
- ✓ Enhanced capability to address entire market segments
- ✓ Increased efficiencies
- Deeper management bench strength
- ✓ Shared customers
- ✓ Simplified structure opens capacity to integrate future acquisitions



Aligning U.S. Lab Support with Apex

- Accelerate Lab Support's growth in highvolume segment of scientific staffing by leveraging Apex's expertise and go-tomarket strategy
- Complements existing retail business
- Enhance ability to train, develop and grow recruiting and sales
- Improve esprit de corps among Lab Support employees







Aligning U.S. Valesta with Oxford

- Both businesses have similar go-to-market approaches
- Leverages Oxford as platform for Valesta growth
- Provides opportunity to pursue higher margin business
- Increases lead-sharing capability







Aligning HIM with Oxford

- Improved collaboration with Oxford Healthcare IT
- Once EHR system implemented by Oxford Healthcare IT, HIM can supply coders to use the system
- Increased opportunity for growth and market share expansion







European Business

- Maintaining single leadership structure
- Concentrate service offerings
- React quickly to market conditions
- Introduce new tools and training programs
- Increase investments to drive sales and recruiting activities









Whitaker Medical – Acquired December 2013

- Combined with VISTA Staffing Solutions
- Pro forma 2013 revenue \$27 million
- Establishes VISTA as 4th largest physician staffing business in the U.S.
- Rapid growth and strong margins
- Improves sub-specialties and geographic coverage







CyberCoders – Acquired December 2013



- SIA reports direct hire growth (16% Y/Y) outpacing temp staffing (12% Y/Y) as of January, 2014*
- Increases mix of perm placement revenue from 1.7% to 4.5%
- Expands gross margin by 175 to 200 bps; increases Adjusted EBITDA margin by 50 bps
- Strong track record of consistent top line growth and high margins
- Accelerate growth through permanent placement leads from On Assignment sales force





Back Office Optimization



- Reduce number of systems supporting back office
- Better absorption of fixed costs
- Component of expanding EBITDA margins
- Building platform to support \$3 billion business
- Detailed planning underway with Deloitte



Experienced & Committed Management Team



Peter Dameri	S
--------------	---

Edward Pierce

James Brill

Michael McGowan

Rand Blazer

Ted Hanson

Christian Rutherford

President & CEO	16 years in industry	10 years with ASGN
Executive VP & CFO	13 years CFO experience	7 years with ASGN
Senior VP, CAO & Treasurer	25 years CFO experience	7 years with ASGN
COO, On Assignment & President, Oxford Global Resources	19 years in industry	7 years with ASGN
President Apex Systems	30 years in industry	2 years with ASGN
CFO, Apex Systems & President, Lab Support	15 years in industry	2 years with ASGN
President VISTA Staffing Solutions	19 years in industry	2 years with ASGN



Five-year Aspirational Financial Goals

- \$3 billion in revenue
- Stable gross margin ~ 32%
- SG&A rate ~ 19.5%
- Adjusted EBITDA margin range: 11.5% to 12.5%
- Cumulative free cash flow of more than \$675 million
- Continued double digit EPS growth



Strategic Focus



Drive organic growth across all operating divisions



Identify additional opportunities to capture cross-selling and back office synergies



pursuit of complementary and accretive acquisitions

On Assignment



Apex


Market: IT Staffing

Rand Blazer

Apex Overview




- Provides mission-critical and emerging IT skill sets to Fortune 500 and mid-market companies
- 200+ National Accounts with a presence in 66 markets
 - Over 16,000 temporary IT professionals staffed annually
- Services clients in 7 industry verticals
- Provides highly skilled IT professionals across 13 skill areas including:
 - Network engineers
 - Application developers
 - Cloud computing
 - Infrastructure
 - Cyber security
- Current statistics:
 - Approximately 7,200 contract professionals at ~600 clients
 - Average bill rate at \$60 an hour
 - Top ten clients represent ~35% of segment revenue





IT Staffing Industry Size and Growth



IT Staffing Growth Drivers



- Constant technology change and specialization
- Growth in IT spend
- Supply/demand imbalance for IT professionals
- Increasing compliance requirements in financial services and healthcare industries
- Aging U.S. population will constrain supply of available workforce
- Healthcare reform will stimulate demand for staffing in the long run
- Changing business model for resource use by CIO's

Emerging Trends Constantly Drive New IT Skill Sets





Financial Services



- Technology has transformed day-to-day operations in the finance sector
- Consolidation amongst industry players continues
- Regulation and innovation
- Global financial markets are increasingly intertwined

Healthcare Digitization



- Healthcare IT is an evolving industry
- IT staffing will be integral to catalogue, cleanse, and support system development
- Conversion to EHR projected to save Medicare and private payers \$50+ billion per year

Mobile/Applications/ Cloud Infrastructure



- Mobile adoption continues to increase rapidly
- Widespread smartphone adoption
- Need for mobile app developers
- Rapidly evolving customer needs
- Cyber security threats are increasing


Social Media



- Extends reach to customers and potential employees
- Corporations are seeking programmers fluent in social media platform development
- Extends brand beyond traditional space



Changing Business Model for CIO's




CIOs balance their use of resources to accomplish:

- Efficient execution
- Flexibility in workforce
- Technology infusion
- Cost optimization
- Risk management and control




Apex Hits the Sweet Spot in Terms of Strategic Value






Apex Financial Performance




Apex Conversion Ratio

GP to Segment Contribution Is Driven by Productivity



Apex Performance vs Market



Apex Go-to-Market Approach





Apex Growth Strategies

Gain market share in existing accounts and add new accounts as we further penetrate Fortune 500





Apex Competitive Advantages



On Assignment



Lab Support

Market: Scientific Staffing

Ted Hanson



Lab Support Business Overview



- Market leader placing science, engineering, and pre-clinical professionals in contract, contract-to-hire and direct hire opportunities.
- Provides highly skilled professionals:
 - Scientists
 - Chemists
 - Biologists
 - Biochemists
 - Lab workers
 - Related Engineering and technical skillsets


Current statistics:

- Approximately 2,000 contract professionals at ~ 800 clients
- Average bill rate at \$30 an hour
- Top 10 clients represent ~28% of division revenue

Business Characteristics:

- Broad mix of skill specialties
- Large and local talent pools
- Centralized buyer programs
- Increasing focus on large customer segment

% of 2013 Revenue by Industry





Aligning U.S. Lab Support with Apex


- Accelerate Lab Support's growth in highvolume segment of scientific staffing by leveraging Apex's expertise and go-tomarket strategy
- Complements existing retail business
- Enhance ability to train, develop and grow recruiting and sales
- Improve esprit de corps among Lab Support employees






Clinical/Scientific Staffing Industry Size and Growth








Lab Support Financial Performance






Lab Support Performance vs Market

Annual Revenue Growth Scientific Staffing Market vs. Lab Support





Lab Support Go-to-Market Approach






60

Lab Support Competitive Advantages





Lab Support Growth Strategies



On Assignment



Oxford Global Resources

Market: High-end IT and Engineering Staffing

Michael McGowan




Oxford Overview



- Disciplined focus on the high-end of select
 IT and engineering markets
 - IT: Enterprise Applications, IT Infrastructure, IT Security, Applications Development
 - Healthcare IT
 - Software/Hardware
 - Engineering: Mechanical, Electrical, Process
 - Regulatory & Compliance: Regulatory Affairs,
 Quality Assurance, Validation
- Proactive, recruiting-driven organization
 - Time sensitive project requirements
 - Significantly higher success rate filling engagements than competitors
- Industry leading bill rates and margins
- Current statistics
 - Approximately 1,740 consultants at 670 clients
 - Average bill rate of \$123 per hour
 - Top ten clients represent ~19% of revenue
 - Average assignment length of ~ 5 months

% of 2013 Revenue by Skill





Industry Dynamics

- U.S. staffing market growth in 2014 forecasted to be approximately
 7% for IT and 5% for engineering
- Demand for senior-level IT and engineering consultants among the most robust in staffing
- The high skill, high bill rate segment of the market characterized by:
 - Scarce talent; typically travels
 - Quality/unique skill of candidate and speed of response most valued
 - Fewer assignments per client
 - Higher margins
- Cycle of current technical skills becoming obsolete and shortages of new technical skills becoming more acute



Oxford's Market Position



Oxford operates in the high skill and bill rate segment of the IT and Engineering markets

Skill Set Market IT **Engineering** Healthcare Clinical/Scientific Segment High Skill & \$100 **Bill Rate** A Division of On Assignment Health Information Management **Mid-tier** \$50 Skill, Volume 🕅 LAB SUPPORT A DIVISION OF ON ASSIGNMENT



Oxford Operating Model: Specialize and Focus

- Core expertise: Recruiting
- Market position: High-end, urgent need
- Skill focus: Select disciplines
- Services: Consulting talent
- Customers: Direct users

The Oxford Process



Identify markets with a critical skills focus


Proactively recruit through personal referrals and references

Utilize network of high-level consultants

React quickly to urgency of client needs


Oxford Financial Performance





Oxford Performance vs Market

Annual Revenue Growth: IT Staffing Market vs. Oxford






Growth Has Been Driven by New Markets




(\$ in millions)





Oxford Competitive Advantages



- Specialize by skill
- Recruiting-driven
 - References and referrals
 - Build relationships
 - Understand interests and availability
- Superior execution
 - Control the hiring process
 - Pre-empt the competition
 - Speed of response
 - High quality candidates
- Process adaptable to new markets



Oxford Growth Strategies

- Staff development
- Top accounts strategy
- Expand Healthcare IT
- Pursue new markets
- Integrate Valesta



Invest in Staff Development to Improve Productivity





- Enhance new hire and on-boarding program
- Develop career paths
- Continue and improve management training




Develop Top Accounts

- Strategic account and territory management
- Leverage national recruiting reach with local presence





Healthcare IT Growth Opportunities



- Short-term: Deploy electronic health records
- Longer-term: Robust analysis of data within EHR systems

Growth beyond clinical applications

- ICD-10
- Revenue Management Systems
- Analytics
- Infrastructure to support advanced analytics
- Emergency Response Systems


Oxford Healthcare IT growth strategies

- Post-EMR implementation services: upgrades, optimization, legacy support
- Expand into growth areas beyond clinical apps
- Develop cross-selling strategy with HIM
- Add sales staff

* Projected


U.S. Healthcare IT Spending for Hardware and Software

(\$ in billions)



Where Some Growth IT Markets Will Be

(\$ in millions)



SOURCE: http://www.cio.com/article/722987/Big_Data_EHR_Driving_Healthcare_IT_Innovation?page=3&taxonomyId=3147, BCC Research, Wellesley, Frost & Sullivan



Pursue New Markets and Service Offerings



- Enhance and expand existing market skill research capability
- Explore new market opportunities
 - Additional segments within IT, Engineering, Regulatory
 - New segments beyond our existing markets
- Consulting (SOW) services



Align U.S. Valesta with Oxford

- Both businesses have similar go-to-market approaches
- Leverages Oxford as platform for Valesta growth
- Provides opportunity to pursue higher margin business
- Increases lead-sharing capability





On Assignment



CyberCoders

Market: Permanent Placement Professional Staffing

Michael McGowan


On Assignment


CyberCoders Overview



- Technology driven model has produced industry-leading revenue growth
- 50% revenue CAGR since 2010 vs. ~18% industry CAGR ¹
- Greater than 25% EBITDA margins, 60% greater than market leader ²
- \$229k ³ revenue per employee
- Seasoned recruiters generate an average of \$262k perm revenue per year
- ~11,000 unique clients and 2,815 perm placements in 2013; no client composing more than 2% of revenue
- ~60% of revenue comes from repeat clients

% of 2013 Revenue






¹ Source: Staffing Industry Analysts (SIA).

² RHI 2012 permanent placement EBITDA margin = 16.7%.



Permanent Placement Market Size and Growth





Permanent Placement Industry Dynamics

- The U.S. direct hire market grew approximately 8% in 2013
- Expected to grow another 8% in 2014 to reach \$8.0 billion
- Growth being driven by increased business confidence
- Recovery of demand from recession declines is expected to continue
- Good timing to invest in permanent placement business






CyberCoders Operating Model

- •
- High tech and high touch
- Revolutionizing recruiting with technology and culture
- Automation at every step of the process
 - Client generation
 - Lead distribution
 - Candidate sourcing
 - New global cloud solution





CyberCoders Financial Performance






CyberCoders Competitive Advantages




- CYRUS platform
- Brand recognition
- Web presence
- Client base
- Scalable
- Centralized recruiting



Unique CYRUS Recruiting Platform







Automated Candidate Sourcing



Knowledge Sharing



Automated Candidate Communication



Automated Client Communication



Gamification to Maximize Productivity

85



Powerful Brand Recognition


- Most jobs, clicks, and networks on LinkedIn
- 60,000+ Facebook fans





Ubiquitous Web Presence

- 2.5 million opt-in recipients
- 700K unique monthly visitors
- 115K web-based applications per month





Strong and Diversified Client Base



- No significant revenue concentration
- 60% of revenue from repeat clients
- Marquee clients in high-growth industries



































Scalable Business Model



Proven compensation structure

Standard recruiter team model

Effective management systems

Work from anywhere systems

Access to broad recruiter talent pool

Analytics-driven sales system

Growth Strategies


- Add recruiters and improve recruiter core
- Increase focus on Staffing and Retained/RPO Lite
- Develop SaaS platform





On Assignment Leads

- On Assignment sales executives uncover a permanent hiring opportunity
- They pass the job lead to CyberCoders through online system
- CyberCoders pursues and qualifies the lead
- On Assignment sales executive receives monetary incentive if the job lead is filled



On Assignment



VISTA

Market: Physician Staffing

Michael McGowan




VISTA Business Overview




- Full-service physician recruitment and staffing company
 - Offering contract staffing solutions to commercial, government, and correctional facilities in a variety of physician specialties
- Places physicians, physician assistants and nurse practitioners throughout the United States, Australia and New Zealand
- Summary statistics:
 - Approximately 30 specialties through 17 employee teams
 - Pool of 2,000+ physicians worldwide, with a range of medical specialties
 - Approximately 325 physicians on assignment daily
 - 40% government mix
 - Average domestic locum tenens assignment lasts 6 weeks
 - 4 month average sales cycle
 - 285 FTE

% of 2013 Revenue by Specialty





Physician Staffing Market Size and Growth





Physician Staffing Market Perspective



- High barriers to entry
- Physician shortage in U.S.
- Approximately 30 million newly insured entering the health care system over the next 12-24 months
- One-third of physician groups are hospital owned
- Top-heavy space




Physician Staffing Industry Dynamics


- Expected shortage of up to 45,000 primary care doctors
- Private practices being consolidated into large hospital systems

in the U.S. by 2020*

- MD's increasingly being employed by hospitals and systems
- The MSP/VMS environment expected to proliferate



VISTA Operating Model















Acquisitive: Purchase of Whitaker Medical positions VISTA as 4th in market

VISTA Financial Performance



VISTA Performance vs Market

Annual Revenue Growth: Physician Staffing Market vs. VISTA





VISTA Diagnosis

Recent Sales Trends

- Headcount and attrition
- Client cycling
- Cancellations

Action Plans

- New senior leadership
- Adding sales staff
- Focus on sales in core locums business
- Retain and penetrate top client base while selling incremental commercial business



VISTA Competitive Advantages



- Broad range of medical specialties
- Broad range of job settings and types
- Strong presence in regions with physician shortages
- Superior satisfaction rate (NPS)
- Industry-leading margins
- Of size to take market share (4th largest)



VISTA Growth Strategies

- Build exclusive client relationships
 - Defend against VMS/MPS
- Expand into new/adjacent markets:
 - Mid-level (NP & PA)
 - Urgent Care
- Invest in high impact subspecialties
 - New teams
 - Dedicated resources





Whitaker Medical – Acquired December 2013

- Pro forma 2013 revenue \$27 million
- Establishes VISTA as fourth largest physician staffing business in U.S.
- Better than industry sales growth trends with good margins
- Expands primary care physician and mid-level coverage
- Expands geographic footprint into south and southeast





On Assignment




Financial Strength,
Segment Reporting Changes & Future Growth

Ed Pierce, Chief Financial Officer




Strong Track Record of Growth






Conversion of Gross Profit to Adj. EBITDA



Adjusted EBITDA & Margin



Note: Results for all periods are the combined results of ASGN and Apex Systems which was acquired on May 15, 2012.

¹ CAGR is calculated using the 4-year period from 2009 to the Reported 2013.

² Pro forma for the acquisitions of CyberCoders and Whitaker Medical as if those acquisitions occurred at the beginning of 2013.

³ Adjusted to exclude benefits related to reductions in earn-out obligations (\$3.5 million in FY 2013).



Selected Operating and Balance Sheet Data



(\$ in millions)

Operating Data (Year Ended December 31):	2013	2012 ¹
Adjusted EBITDA	\$172.2	\$125.4
Cash Flows from Operating Activities	110.5	40.7
Capital Expenditures	16.5	14.4
Free Cash Flow	94.0	26.3
Free Cash Flow as a percent of Adjusted EBITDA	54.6%	21.0%
Balance Sheet Data (as of December 31):		
Cash and Cash Equivalents	\$37.4	\$27.5
Working Capital	180.9	177.2
Long-term Debt (includes current portion)	399.8	426.6
Shareholders' Equity	640.1	532.7
Leverage Ratio (debt to trailing 12-months EBITDA)	2.20x	2.88x



New Segment Reporting

F	orma 2013¹ (\$ in millions)	Pre- Realignment	% of Total		Post Realignmen
	Apex	\$942.5	54.9%	Apex (incl. Lab Support US)	\$1,060.0
	Oxford ²	471.8	27.5%		
	Life Sciences:			Oxford ² (incl. Clinical Research US)	483.3
	Lab Support US	117.5	6.8%		
	Clinical Research US	11.5	0.7%	Physician ³	130.8
	Other (Europe)	42.5	2.5%		
	Total	171.5	10.0%	Other (Life Sciences Europe)	42.5
	Physician ³	130.8	7.6%		
	Consolidated Revenues	\$1,716.5		Consolidated Revenues	\$1,716.5
	Apex	\$258.2	47.2%	Apex (incl. Lab Support US)	\$294.6
	Oxford ²	194.2	35.5%		
	Life Sciences:			Oxford ² (incl. Clinical Research US)	198.2
	Lab Support US	36.5	6.7%		
	Clinical Research US	4.0	0.7%	Physician ³	38.5
	Other (Europe)	15.8	2.9%		
	Total	56.3	10.3%	Other (Life Sciences Europe)	15.8
	Physician ³	38.5	7.0%		
	Consolidated Gross Profit	\$547.1		Consolidated Gross Profit	\$547.1

¹ Pro forma assumes acquisitions of CyberCoders and Whitaker Medical occurred at the beginning of the year.

² Oxford includes full year 2013 results of CyberCoders.

³ Physician includes full year 2013 results of Whitaker Medical.

Key Assumptions Underlying 5-Year Growth in Adjusted EBITDA & Earnings





Revenue Growth

- Assumes 10 percent year-over-year organic revenue growth in current base of business
- Organic growth will be augmented by revenues from acquisitions, which is estimated to contribute at least \$240 million in 2018 to reach \$3 billion revenue target
- Organic revenue growth of 10 percent assumes continuation of current macroeconomic trends and assumes growth above estimated industry market rates

Maintain Gross Margins of 31-32%

- Assumes shift in mix of revenues toward higher volume/lower margin business (i.e. higher growth in Apex Segment)
- Compression in margin caused by shift in mix of revenues partially offset by higher mix of permanent placement revenues

Improved Operating Leverage

- Assumes a 2 percentage point reduction in cash SG&A expenses as a percent of sales
- Improvement driven by:
 - Increase in staffing consultant productivity from the operational realignment
 - Greater economies of scale due to growth in the business
 - Higher efficiencies related to integration/consolidation initiatives

Higher Growth in EPS than Adjusted EBITDA

- Free cash flow (FCF) generated over 5-year period of \$675 to \$700 million will be used to:
 - Pay-down indebtedness resulting in lower interest expense
 - Fund a significant portion of the costs of future acquisitions and pay-down acquisition borrowings
 - Repurchase common stock out of FCF not used for acquisitions or debt repayment
- Lower effective tax rate as pre-tax income should grow faster than book-to-tax permanent differences
- Lower amortization of intangible assets due to high amortization rates in earlier years



2018 Estimates Compared with Pro Forma 2013

(\$ in millions)

Year Ended(ing) December 31	Pro Forma 2013 ¹	2018	5-Year CAGR
Revenues	\$1,717	\$3,000 ²	11.8%²
Gross Profit	547	930 - 960	11.2% - 11.9%
Cash SG&A Expenses	369	585	9.7%
Adjusted EBITDA	183	345 - 375	13.5% - 15.4%
Free Cash Flow	94	175 - 195	13.2% - 15.7%
Margins:			
Gross	31.9%	31.0% - 32.0% ³	
Cash SG&A Expense (as % of revenues)	21.5%	19.5% - 19.5% 4	
Adjusted EBITDA	10.7%	11.5% - 12.5%	
Conversion of Gross Profit into Adjusted EBITDA	33.5%	37.1% - 39.1%	

¹ Includes the results for Whitaker Medical & CyberCoders as if these acquisitions had occurred at the beginning of the year.

² Year-over-year revenue growth of 10 percent and contribution of approximately \$240 million from future acquisitions.

³ Margin remains stable over 5-year period and assumes higher mix from higher volume/lower margin segment, partially offset by a higher mix of revenues from permanent placement. High-end of margin assumes higher contribution from permanent placement.

⁴ Improvement in operating leverage driven by the operational realignment, higher economies of scale and cost savings from integration/consolidation initiatives.



Adjusted Net Earnings



Adjusted Net Earnings (a non-GAAP measurement) is considered by management to be:

- A better indicator of operating performance than GAAP earnings; and
- Improves the comparability of the Company's earnings with those of non-acquisitive companies

Adjustments to GAAP earnings to derive Adjusted Net Earnings relate to the accounting effects of acquisitions. Principal adjustments include add-backs for:

- Non-cash amortization of identifiable intangible assets for financial reporting purposes; and
- Cash income tax benefit from the income tax deduction of amortization of Goodwill & Trademarks
 - The income tax deduction relates to the step-up in tax basis in the acquired assets of certain acquisitions resulting from a Sec. 338(h)10 election, which treats a stock purchase as an asset purchase for income tax purposes
 - These assets are not deductible for GAAP purposes and the cash income tax benefit is fully offset by a deferred tax provision

Certain sell-side analysts include Adjusted EPS in their financial models but all do not use the same methodology employed by the Company

Adjusted Net Earnings (continued)



(\$ in millions)

Year ending December 31, Add-backs	2014	2015	2016	2017	2018
Amortization of identifiable assets ¹	\$24.5	\$21.3	\$17.7	\$12.9	\$10.3
Cash income tax savings on amortization of indefinite-lived intangible assets (Goodwill & Trademarks) ²	16.1	16.1	16.1	16.1	16.1
Deductions					
Estimated excess of capital expenditures over depreciation, net-of-tax	(4.1)	(2.7)	(2.1)	(1.4)	(1.2)
Income taxes on amortization for financial reporting purposes not deductible for income tax purposes ³	(2.1)	(2.0)	(1.6)	(1.2)	(1.2)
Net Adjustment to GAAP Net Income to Calculate Adjusted Net Income	\$34.4	\$32.7	\$30.1	\$26.3	\$24.0

Notes:

Table above shows adjustments to GAAP Net Income to calculate Adjusted Net Income.

- ¹ Amortization of identifiable intangible assets (e.g., customer/contractor relationships, non-compete agreements, etc.) related to the acquired businesses. The year-over-year reductions in this add-back will result in a corresponding increase in operating income for GAAP purposes.
- Income tax benefit (using 39 percent marginal tax rate) from amortization for income tax purposes of certain indefinite-lived intangible assets (goodwill & trademarks), on acquisitions in which the company received a step-up in tax basis. For income tax purposes, these assets are amortized on a straight-line basis over 15 years. For financial reporting purposes, these assets are not amortized and a deferred tax provision is recorded that fully offsets the cash tax benefit in the determination of net income.
- ³ Income taxes (assuming a 39 percent marginal rate) on the portion of amortization of identifiable intangible assets, which are not deductible for income tax purposes (mainly amortization associated with the CyberCoders acquisition that the Company was not able to step-up the tax basis in those acquired assets for tax purposes).



Key Considerations

- Strong track record of growth
- Proven acquisition strategy
- Operate in dynamic and growing markets
- Realigned businesses to drive growth and operating leverage
- Strong and committed management team

On Assignment



On Assignment, Inc. 2014 Analyst Day

March 26, 2014







Contents

Historical Segment Data (Revised for Changes in Reporting Structure)

Revenues	A-2
Gross profit	A-3

Statistical dataA-4

Adjusted Income from Continuing Operations & Related per Share Amounts

2013	A-5
------	-----

2012 A-6

Historical Segment Data (Revised for Changes in Reporting Structure)





		20	12			2013							
(\$ in thousands)	Q1	Q2		Q3	Q4		Q1		Q2		Q3		Q4
Total Revenues:													
Apex ¹	\$ 27,453	\$ 125,781	\$	229,936	\$ 234,674	\$	239,765	\$	262,347	\$	276,849	\$	281,032
Oxford ²	85,328	95,001		96,274	98,594		102,688		109,153		107,413		104,416
Physician	24,089	25,039		27,479	26,072		26,302		26,466		26,223		26,836
Other ³	11,407	10,565		10,193	10,101		10,289		9,898		11,006		11,314
Consolidated	\$ 148,277	\$ 256,386	\$	363,882	\$ 369,441	\$	379,044	\$	407,864	\$	421,491	\$	423,598
Direct hire and conversion revenues:													
Apex ¹	\$ 869	\$ 2,056	\$	3,535	\$ 3,277	\$	3,229	\$	2,968	\$	3,414	\$	3,221
Oxford ²	1,674	2,078		1,536	1,395		1,903		1,789		1,613		4,065
Physician	1,133	664		1,239	824		1,019		632		1,033		746
Other ³	1,295	910		874	1,069		1,027		823		1,120		838
Consolidated	\$ 4,971	\$ 5,708	\$	7,184	\$ 6,565	\$	7,178	\$	6,212	\$	7,180	\$	8,870
As a percent of Consolidated Revenues	 3.4%	2.2%		2.0%	 1.8%		1.9%		1.5%		1.7%		2.1%

The tables above reflect the retrospective restatement to (i) exclude the results of Nurse Travel and Allied Healthcare, which were sold in 2013 and are reported as discontinued operations and (ii) present the data according to new reporting scheme following the operational realignment that occurred in the first quarter of 2014. The changes to the reporting segment were to move (i) Lab Support U.S. (formerly part of the Life Sciences Segment) to Apex Systems and (ii) Clinical Research (formerly part of the Life Sciences Segment) to Oxford and report the European operations of Life Sciences as Other.

¹ Apex Segment is comprised of Apex Systems and Lab Support U.S. (formerly part of the Life Sciences Segment). Apex Systems was acquired on May 15, 2012 and its results are included from the date of acquisition.

² Oxford Segment is comprised of Oxford, the Health Information Management division (formerly part of the Healthcare Segment), the Clinical Research division (formerly part of the Life Sciences Segment) and CyberCoders, which was acquired in December 2013 and included from the date of acquisition.

Other is the European operations of Life Sciences (formerly part of the Life Sciences Seament).

Historical Segment Data (Revised for Changes in Reporting Structure) - Cont'd



		20	12							20	13			
Q1		Q2		Q3		Q4		Q1		Q2		Q3		Q4
\$ 8,069	\$	35,804	\$	65,701	\$	65,394	\$	63,981	\$	72,912	\$	78,854	\$	78,864
29,779		33,925		34,028		34,302		34,815		37,122		36,825		38,586
7,499		7,718		8,370		7,868		7,483		7,640		7,382		8,109
4,770		4,062		4,114		4,490		3,832		3,658		4,149		4,194
\$ 50,117	\$	81,509	\$	112,213	\$	112,054	\$	110,111	\$	121,332	\$	127,210	\$	129,753
29.4%		28.5%		28.6%		27.9%		26.7%		27.8%		28.5%		28.1%
34.9%		35.7%		35.3%		34.8%		33.9%		34.0%		34.3%		37.0%
31.1%		30.8%		30.5%		30.2%		28.5%		28.9%		28.2%		30.2%
41.8%		38.4%		40.4%		44.5%		37.2%		37.0%		37.7%		37.1%
33.8%		31.8%		30.8%		30.3%		29.0%		29.7%		30.2%		30.6%
\$ 84,000	\$	50,000	\$	88,000	\$	86,000	\$	83,000	\$	94,000	\$	99,000	\$	98,000
58,000		64,000		63,000		60,000		62,000		65,000		63,000		58,000
79,000		79,000		82,000		73,000		70,000		77,000		79,000		77,000
81,000		73,000		73,000		76,000		65,000		53,000		66,000		71,000
66,000		58,000		78,000		75,000		73,000		80,000		83,000		80,000
\$	\$ 8,069 29,779 7,499 4,770 \$ 50,117 29.4% 34.9% 31.1% 41.8% 33.8% \$ 84,000 58,000 79,000 81,000	\$ 8,069 \$ 29,779 7,499 4,770 \$ 50,117 \$ 29.4% 34.9% 31.1% 41.8% 33.8% \$ 84,000 \$ 58,000 79,000 81,000	\$ 8,069 \$ 35,804 29,779 33,925 7,499 7,718 4,770 4,062 \$ 50,117 \$ 81,509 29.4% 28.5% 34.9% 35.7% 31.1% 30.8% 41.8% 38.4% 33.8% 31.8% \$ 84,000 \$ 50,000 58,000 64,000 79,000 79,000 81,000 73,000	\$ 8,069 \$ 35,804 \$ 29,779 33,925 7,499 7,718 4,770 4,062 \$ 50,117 \$ 81,509 \$ \$ 29.4% 28.5% 34.9% 35.7% 31.1% 30.8% 41.8% 38.4% 33.8% 31.8% \$ 84,000 \$ 50,000 \$ 58,000 64,000 79,000 81,000 73,000	Q1 Q2 Q3 \$ 8,069 \$ 35,804 \$ 65,701 29,779 33,925 34,028 7,499 7,718 8,370 4,770 4,062 4,114 \$ 50,117 \$ 81,509 \$ 112,213 29.4% 28.5% 28.6% 34.9% 35.7% 35.3% 31.1% 30.8% 30.5% 41.8% 38.4% 40.4% 33.8% 31.8% 30.8% \$ 84,000 \$ 50,000 \$ 88,000 58,000 64,000 63,000 79,000 79,000 82,000 81,000 73,000 73,000	Q1 Q2 Q3 \$ 8,069 \$ 35,804 \$ 65,701 \$ 29,779 33,925 34,028 7,499 7,718 8,370 4,770 4,062 4,114 \$ 50,117 \$ 81,509 \$ 112,213 \$ 29.4% 28.5% 28.6% 34.9% 35.7% 35.3% 31.1% 30.8% 30.5% 41.8% 38.4% 40.4% 33.8% 31.8% 30.8% \$ 84,000 \$ 50,000 \$ 88,000 \$ \$ 84,000 \$ 50,000 \$ 88,000 \$ \$ 84,000 79,000 82,000 82,000 81,000 73,000 73,000 73,000	Q1 Q2 Q3 Q4 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 29,779 33,925 34,028 34,302 7,499 7,718 8,370 7,868 4,770 4,062 4,114 4,490 \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 29.4% 28.5% 28.6% 27.9% 34.9% 35.7% 35.3% 34.8% 31.1% 30.8% 30.5% 30.2% 41.8% 38.4% 40.4% 44.5% 33.8% 31.8% 30.8% 30.8% 30.3% \$ 84,000 \$ 50,000 \$ 88,000 \$ 86,000 58,000 64,000 63,000 60,000 79,000 79,000 79,000 73,000 76,000	Q1 Q2 Q3 Q4 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 29,779 33,925 34,028 34,302 7,868 4,770 4,062 4,114 4,490 4,490 4,4490 4,4490 5 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 5 28.6% 27.9% 34.9% 35.7% 35.3% 34.8% 31.1% 30.8% 30.5% 30.2% 41.8% 38.4% 40.4% 44.5% 33.8% 31.8% 30.8% 30.3% 30.3% \$ \$ \$8,000 \$ 86,000 \$ 58,000 \$ 86,000 \$ 79,000 \$ 79,000 73,000 73,000 73,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000 76,000	Q1 Q2 Q3 Q4 Q1 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 29,779 33,925 34,028 34,302 34,815 7,499 7,718 8,370 7,868 7,483 4,770 4,062 4,114 4,490 3,832 \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 29.4% 28.5% 28.6% 27.9% 26.7% 34.9% 35.7% 35.3% 34.8% 33.9% 31.1% 30.8% 30.5% 30.2% 28.5% 41.8% 38.4% 40.4% 44.5% 37.2% 33.8% 31.8% 30.8% 30.3% 29.0% \$ 84,000 \$ 50,000 \$ 88,000 \$ 86,000 \$ 83,000 \$ 84,000 \$ 50,000 \$ 82,000 73,000 70,000 \$ 79,000 79,000 73,000 76,000 65,000	Q1 Q2 Q3 Q4 Q1 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 \$ 29,779 33,925 34,028 34,302 34,815 7,499 7,718 8,370 7,868 7,483 4,770 4,062 4,114 4,490 3,832 \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 \$ \$ 29.4% 28.5% 28.6% 27.9% 26.7% 26.7% 34.9% 35.7% 35.3% 34.8% 33.9% 31.1% 30.8% 30.5% 30.2% 28.5% 41.8% 38.4% 40.4% 44.5% 37.2% 33.8% 31.8% 30.8% 30.3% 29.0% \$ 84,000 \$ 80,000 \$ 86,000 \$ 83,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 \$ 80,000 <td>Q1 Q2 Q3 Q4 Q1 Q2 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 \$ 72,912 29,779 33,925 34,028 34,302 34,815 37,122 7,499 7,718 8,370 7,868 7,483 7,640 4,770 4,062 4,114 4,490 3,832 3,658 \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 \$ 121,332 29.4% 28.5% 28.6% 27.9% 26.7% 27.8% 34.9% 35.7% 35.3% 34.8% 33.9% 34.0% 31.1% 30.8% 30.5% 30.2% 28.5% 28.9% 41.8% 38.4% 40.4% 44.5% 37.2% 37.0% 33.8% 31.8% 30.8% 30.3% 29.0% 29.7% \$ 84,000 \$ 86,000 \$ 83,000 \$ 94,000 58,000 64,000 63,000 60,000 62,000 65,000<td>Q1 Q2 Q3 Q4 Q1 Q2 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 \$ 72,912 \$ 29,779 33,925 34,028 34,302 34,815 37,122 7,499 7,718 8,370 7,868 7,483 7,640 4,770 4,062 4,114 4,490 3,832 3,658 \$ \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 \$ 121,332 \$ 29.4% 28.5% 28.6% 27.9% 26.7% 27.8% 34.9% 35.7% 35.3% 34.8% 33.9% 34.0% 31.1% 30.8% 30.5% 30.2% 28.5% 28.9% 41.8% 38.4% 40.4% 44.5% 37.2% 37.0% 33.8% 31.8% 30.8% 30.3% 29.0% 29.7% \$ 84,000 \$ 50,000 \$ 88,000 \$ 86,000 \$ 83,000 \$ 94,000 \$ 58,000 64,000 63,000 60,000 62,000 65,000 79,000 79,000 79,000 82,000 73,000 70,000 77,000 81,000 73,000 73,000 76,000 65,000 53,000</td><td>Q1 Q2 Q3 Q4 Q1 Q2 Q3 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 \$ 72,912 \$ 78,854 29,779 33,925 34,028 34,302 34,815 37,122 36,825 7,499 7,718 8,370 7,868 7,483 7,640 7,382 4,770 4,062 4,114 4,490 3,832 3,658 4,149 \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 \$ 121,332 \$ 127,210 29.4% 28.5% 28.6% 27.9% 26.7% 27.8% 28.5% 34.9% 35.7% 35.3% 34.8% 33.9% 34.0% 34.3% 31.1% 30.8% 30.5% 30.2% 28.5% 28.9% 28.2% 41.8% 38.4% 40.4% 44.5% 37.2% 37.0% 37.7% 33.8% 31.8% 30.8% 30.3% 29.0% 29.7% 30.2% \$ 84,000<td>Q1 Q2 Q3 Q4 Q1 Q2 Q3 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 \$ 72,912 \$ 78,854 \$ 29,779 33,925 34,028 34,302 34,815 37,122 36,825 7,499 7,718 8,370 7,868 7,483 7,640 7,382 4,770 4,062 4,114 4,490 3,832 3,658 4,149 \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 \$ 121,332 \$ 127,210 \$ 29.4% 28.5% 28.6% 27.9% 26.7% 27.8% 28.5% 34.9% 35.7% 35.3% 34.8% 33.9% 34.0% 34.3% 31.1% 30.8% 30.5% 30.2% 28.5% 28.9% 28.2% 41.8% 38.4% 40.4% 44.5% 37.2% 37.0% 37.7% 33.8% 31.8% 30.8% 30.3% 29.0% 29.7% 30.2%</td></td></td>	Q1 Q2 Q3 Q4 Q1 Q2 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 \$ 72,912 29,779 33,925 34,028 34,302 34,815 37,122 7,499 7,718 8,370 7,868 7,483 7,640 4,770 4,062 4,114 4,490 3,832 3,658 \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 \$ 121,332 29.4% 28.5% 28.6% 27.9% 26.7% 27.8% 34.9% 35.7% 35.3% 34.8% 33.9% 34.0% 31.1% 30.8% 30.5% 30.2% 28.5% 28.9% 41.8% 38.4% 40.4% 44.5% 37.2% 37.0% 33.8% 31.8% 30.8% 30.3% 29.0% 29.7% \$ 84,000 \$ 86,000 \$ 83,000 \$ 94,000 58,000 64,000 63,000 60,000 62,000 65,000 <td>Q1 Q2 Q3 Q4 Q1 Q2 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 \$ 72,912 \$ 29,779 33,925 34,028 34,302 34,815 37,122 7,499 7,718 8,370 7,868 7,483 7,640 4,770 4,062 4,114 4,490 3,832 3,658 \$ \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 \$ 121,332 \$ 29.4% 28.5% 28.6% 27.9% 26.7% 27.8% 34.9% 35.7% 35.3% 34.8% 33.9% 34.0% 31.1% 30.8% 30.5% 30.2% 28.5% 28.9% 41.8% 38.4% 40.4% 44.5% 37.2% 37.0% 33.8% 31.8% 30.8% 30.3% 29.0% 29.7% \$ 84,000 \$ 50,000 \$ 88,000 \$ 86,000 \$ 83,000 \$ 94,000 \$ 58,000 64,000 63,000 60,000 62,000 65,000 79,000 79,000 79,000 82,000 73,000 70,000 77,000 81,000 73,000 73,000 76,000 65,000 53,000</td> <td>Q1 Q2 Q3 Q4 Q1 Q2 Q3 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 \$ 72,912 \$ 78,854 29,779 33,925 34,028 34,302 34,815 37,122 36,825 7,499 7,718 8,370 7,868 7,483 7,640 7,382 4,770 4,062 4,114 4,490 3,832 3,658 4,149 \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 \$ 121,332 \$ 127,210 29.4% 28.5% 28.6% 27.9% 26.7% 27.8% 28.5% 34.9% 35.7% 35.3% 34.8% 33.9% 34.0% 34.3% 31.1% 30.8% 30.5% 30.2% 28.5% 28.9% 28.2% 41.8% 38.4% 40.4% 44.5% 37.2% 37.0% 37.7% 33.8% 31.8% 30.8% 30.3% 29.0% 29.7% 30.2% \$ 84,000<td>Q1 Q2 Q3 Q4 Q1 Q2 Q3 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 \$ 72,912 \$ 78,854 \$ 29,779 33,925 34,028 34,302 34,815 37,122 36,825 7,499 7,718 8,370 7,868 7,483 7,640 7,382 4,770 4,062 4,114 4,490 3,832 3,658 4,149 \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 \$ 121,332 \$ 127,210 \$ 29.4% 28.5% 28.6% 27.9% 26.7% 27.8% 28.5% 34.9% 35.7% 35.3% 34.8% 33.9% 34.0% 34.3% 31.1% 30.8% 30.5% 30.2% 28.5% 28.9% 28.2% 41.8% 38.4% 40.4% 44.5% 37.2% 37.0% 37.7% 33.8% 31.8% 30.8% 30.3% 29.0% 29.7% 30.2%</td></td>	Q1 Q2 Q3 Q4 Q1 Q2 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 \$ 72,912 \$ 29,779 33,925 34,028 34,302 34,815 37,122 7,499 7,718 8,370 7,868 7,483 7,640 4,770 4,062 4,114 4,490 3,832 3,658 \$ \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 \$ 121,332 \$ 29.4% 28.5% 28.6% 27.9% 26.7% 27.8% 34.9% 35.7% 35.3% 34.8% 33.9% 34.0% 31.1% 30.8% 30.5% 30.2% 28.5% 28.9% 41.8% 38.4% 40.4% 44.5% 37.2% 37.0% 33.8% 31.8% 30.8% 30.3% 29.0% 29.7% \$ 84,000 \$ 50,000 \$ 88,000 \$ 86,000 \$ 83,000 \$ 94,000 \$ 58,000 64,000 63,000 60,000 62,000 65,000 79,000 79,000 79,000 82,000 73,000 70,000 77,000 81,000 73,000 73,000 76,000 65,000 53,000	Q1 Q2 Q3 Q4 Q1 Q2 Q3 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 \$ 72,912 \$ 78,854 29,779 33,925 34,028 34,302 34,815 37,122 36,825 7,499 7,718 8,370 7,868 7,483 7,640 7,382 4,770 4,062 4,114 4,490 3,832 3,658 4,149 \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 \$ 121,332 \$ 127,210 29.4% 28.5% 28.6% 27.9% 26.7% 27.8% 28.5% 34.9% 35.7% 35.3% 34.8% 33.9% 34.0% 34.3% 31.1% 30.8% 30.5% 30.2% 28.5% 28.9% 28.2% 41.8% 38.4% 40.4% 44.5% 37.2% 37.0% 37.7% 33.8% 31.8% 30.8% 30.3% 29.0% 29.7% 30.2% \$ 84,000 <td>Q1 Q2 Q3 Q4 Q1 Q2 Q3 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 \$ 72,912 \$ 78,854 \$ 29,779 33,925 34,028 34,302 34,815 37,122 36,825 7,499 7,718 8,370 7,868 7,483 7,640 7,382 4,770 4,062 4,114 4,490 3,832 3,658 4,149 \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 \$ 121,332 \$ 127,210 \$ 29.4% 28.5% 28.6% 27.9% 26.7% 27.8% 28.5% 34.9% 35.7% 35.3% 34.8% 33.9% 34.0% 34.3% 31.1% 30.8% 30.5% 30.2% 28.5% 28.9% 28.2% 41.8% 38.4% 40.4% 44.5% 37.2% 37.0% 37.7% 33.8% 31.8% 30.8% 30.3% 29.0% 29.7% 30.2%</td>	Q1 Q2 Q3 Q4 Q1 Q2 Q3 \$ 8,069 \$ 35,804 \$ 65,701 \$ 65,394 \$ 63,981 \$ 72,912 \$ 78,854 \$ 29,779 33,925 34,028 34,302 34,815 37,122 36,825 7,499 7,718 8,370 7,868 7,483 7,640 7,382 4,770 4,062 4,114 4,490 3,832 3,658 4,149 \$ 50,117 \$ 81,509 \$ 112,213 \$ 112,054 \$ 110,111 \$ 121,332 \$ 127,210 \$ 29.4% 28.5% 28.6% 27.9% 26.7% 27.8% 28.5% 34.9% 35.7% 35.3% 34.8% 33.9% 34.0% 34.3% 31.1% 30.8% 30.5% 30.2% 28.5% 28.9% 28.2% 41.8% 38.4% 40.4% 44.5% 37.2% 37.0% 37.7% 33.8% 31.8% 30.8% 30.3% 29.0% 29.7% 30.2%

The tables above reflect the retrospective restatement to (i) exclude the results of Nurse Travel and Allied Healthcare, which were sold in 2013 and are reported as discontinued operations and (ii) present the data according to new reporting scheme following the operational realignment that occurred in the first quarter of 2014. The changes to the reporting segment were to move (i) Lab Support U.S. (formerly part of the Life Sciences Segment) to Apex Systems and (ii) Clinical Research (formerly part of the Life Sciences Segment) to Oxford and report the European operations of Life Sciences as Other.

A-3

¹ Apex Segment is comprised of Apex Systems and Lab Support U.S. (formerly part of the Life Sciences Segment). Apex Systems was acquired on May 15, 2012 and its results are included from the date of acquisition.

² Oxford Segment is comprised of Oxford, the Health Information Management division (formerly part of the Healthcare Segment), the Clinical Research division (formerly part of the Life Sciences Segment) and CyberCoders, which was acquired in December 2013 and included from the date of acquisition.

Other is the European operations of Life Sciences (formerly part of the Life Sciences Segment).

⁴ Data for the 2nd quarter of 2012 are calculated using reported results that include Apex Systems from the date of acquisition (May 15, 2012) through the end of the period. Pro forma gross profit per staffing consultant, which assumes Apex Systems was acquired at the beginning of the quarter, was \$87,000 for the Apex Segment and \$77,000 on a consolidated basis.

Historical Segment Data (Revised for Changes in Reporting Structure) - Cont'd



			20	12				20	13		
		21	Q2	12	Q3	Q4	Q1	Q2	13	Q3	Q4
Contract professionals (total)		3,973	10,408		10,705	10,760	10,834	11,199		11,763	12,363
Average number of staffing consultants:											
Apex ¹		96	723		747	763	772	777		796	805
Oxford ²		514	526		539	574	565	572		580	660
Physician		95	98		103	108	107	100		93	106
Other ³		59	56		56	59	59	69		63	59
Consolidated		764	1,403		1,445	1,504	1,503	1,518		1,532	1,630
Average number of customers:		,									
Apex ¹		733	1,320		1,346	1,358	1,312	1,331		1,345	1,381
Oxford ²		708	736		741	742	747	770		757	892
Physician		175	186		194	180	173	177		188	214
Other ³		161	154		161	153	144	147		148	156
Consolidated		1,777	2,396		2,442	2,433	2,376	2,425		2,438	2,643
Top 10 customers as a percentage of revenues:			<u>.</u> ,								
Apex ^{1,4}		22.1%	29.4%		29.2%	30.4%	29.7%	30.3%		35.1%	31.1%
Oxford ²		14.5%	15.2%		14.2%	14.5%	15.5%	18.9%		17.2%	14.6%
Physician		22.0%	19.8%		19.2%	22.1%	21.6%	22.3%		21.4%	20.9%
Other ³		50.9%	57.1%		50.1%	55.8%	54.4%	62.8%		55.0%	54.3%
Consolidated		10.4%	18.9%		18.8%	19.9%	19.1%	19.8%		20.5%	20.6%
Average bill rate:											
Apex ¹	\$	30.13	\$ 53.06	\$	53.06	\$ 52.80	\$ 53.59	\$ 54.26	\$	54.10	\$ 53.41
Oxford ²	:	112.85	114.53		113.73	116.25	117.67	118.25		116.80	113.75
Physician	:	175.63	175.11		181.59	184.57	185.92	183.95		182.71	186.44
Other ³		52.10	52.95		52.46	53.90	53.95	53.57		51.68	51.91
Consolidated		67.82	64.82		65.23	65.32	65.89	66.54		65.29	64.11

The tables above reflect the retrospective restatement to (i) exclude the results of Nurse Travel and Allied Healthcare, which were sold in 2013 and are reported as discontinued operations and (ii) present the data according to new reporting scheme following the operational realignment that occurred in the first quarter of 2014. The changes to the reporting segment were to move (i) Lab Support U.S. (formerly part of the Life Sciences Segment) to Apex Systems and (ii) Clinical Research (formerly part of the Life Sciences Segment) to Oxford and report the European operations of Life Sciences as Other.

¹ Apex Segment is comprised of Apex Systems and Lab Support U.S. (formerly part of the Life Sciences Segment). Apex Systems was acquired on May 15, 2012 and its results are included from the date of acquisition.

² Oxford Segment is comprised of Oxford, the Health Information Management division (formerly part of the Healthcare Segment), the Clinical Research division (formerly part of the Life Sciences Segment) and CyberCoders, which was acquired in December 2013 and included from the date of acquisition.

³ Other is the European operations of Life Sciences (formerly part of the Life Sciences Segment).

⁴ Data for the 2nd quarter of 2012 are on a pro forma basis as if Apex Systems was acquired at the beginning of the quarter.

Adjusted Income from Continuing Operations & Related per Share Amounts for 2013



\$ in thousands, except per share amounts)	Q1	Q2	Q3	Q4	F	ull Year
ncome from Continuing Operations - GAAP Basis ¹	\$ 10,216	\$ 7,243	\$ 19,471	\$ 17,425	\$	54,355
Add-backs for:						
Write-off of loan costs related to refinancing, net of income taxes	-	9,181	-	-		9,181
Acquisition-related expenses, net of income taxes	93	143	159	1,296		1,69
Strategic planning expenses, net of income taxes	281	249	152	246		92
Ion-GAAP Income from Continuing Operations	10,590	16,816	19,782	18,967		66,155
djustments to Calculate Adjusted Income from Continuing Operations:						
Add-back for						
Amortization of identifiable intangible assets ²	5,379	5,275	5,199	5,898		21,75
Cash income tax savings on amortization of indefinite-lived						
intangible assets (Goodwill & Trademarks) ³	3,850	3,850	3,850	4,015		15,56
Deductions for						
Estimated excess of capital expenditures over depreciation,						
net-of-tax	(1,050)	(1,050)	(1,050)	(1,050)		(4,20
Income taxes on amortization for GAAP purposes not						
deductible for income tax purposes ⁴	-	-	-	(347)		(34
djusted Income from Continuing Operations (non-GAAP measurement)	\$ 18,769	\$ 24,891	\$ 27,781	\$ 27,483	\$	98,92
ncome from Continuing Operations per Diluted Share:						
GAAP Basis	\$ 0.19	\$ 0.13	\$ 0.36	\$ 0.32	\$	1.0
Non-GAAP	\$ 0.20	\$ 0.31	\$ 0.36	\$ 0.35	\$	1.2
Adjusted (non-GAAP measurement)	\$ 0.35	\$ 0.46	\$ 0.51	\$ 0.50	\$	1.8

¹ Historical results on a GAAP basis have been retroactively restated to exclude from continuing operations the results of Nurse Travel and Allied Healthcare, which were sold in 2013.

A-5

² Amortization of identifiable intangible assets (e.g., customer/contractor relationships, non-compete agreements, etc.) related to acquired businesses.

Income tax benefits (using a 39 percent marginal tax rate) from amortization for income tax purposes of indefinite-lived assets (Goodwill & Trademarks) on acquisitions that the Company obtained a full tax-basis step up in the assets acquired. For income tax purposes, these assets are amortized on a straight-line basis over 15 years. For financial reporting purposes, these assets are not amortized and a deferred tax provision is recorded that fully offsets the cash tax benefit in the determination of net income.

⁴ Income taxes (using a 39 percent marginal rate) on the portion of amortization of intangible assets that are non-deductible for income tax purposes (amortization related to CyberCoders, which is not deductible for tax purposes).

Adjusted Income from Continuing Operations & Related per Share Amounts for 2012





(\$ in thousands, except per share amounts)	Q1	Q2	Q3	Q4	F	ull Year
Income from Continuing Operations - GAAP Basis ¹	\$ 4,791	\$ 5,586	\$ 14,078	\$ 12,004	\$	36,459
Add-backs for:						
Write-off of loan costs related to refinancing, net of income taxes	-	701	-	-		701
Acquisition-related expenses, net of income taxes	1,451	3,788	649	(56)		5,832
Strategic planning expenses, net of income taxes	-	-	-	-		-
Non-GAAP Income from Continuing Operations	6,242	10,075	14,727	11,948		42,992
Adjustments to Calculate Adjusted Income from Continuing Operations:						
Add-back for						
Amortization of identifiable intangible assets ²	634	3,884	6,679	6,819		18,016
Cash income tax savings on amortization of indefinite-lived						
intangible assets (Goodwill & Trademarks) ³	1,151	2,496	3,850	3,850		11,347
Deductions for						
Estimated excess of capital expenditures over depreciation,						
net-of-tax	(453)	(2,150)	(1,188)	(1,019)		(4,810)
Income taxes on amortization for GAAP purposes not						
deductible for income tax purposes ⁴	-	-	-	-		-
Adjusted Income from Continuing Operations (non-GAAP measurement)	\$ 7,574	\$ 14,305	\$ 24,068	\$ 21,598	\$	67,544
Income from Continuing Operations per Diluted Share:						
GAAP Basis	\$ 0.13	\$ 0.12	\$ 0.26	\$ 0.22	\$	0.76
Non-GAAP	\$ 0.16	\$ 0.22	\$ 0.28	\$ 0.22	\$	0.90
Adjusted (non-GAAP measurement)	\$ 0.20	\$ 0.31	\$ 0.45	\$ 0.40	\$	1.41

¹ Historical results on a GAAP basis have been retroactively restated to exclude from continuing operations the results of Nurse Travel and Allied Healthcare, which were sold in 2013.

² Amortization of identifiable intangible assets (e.g., customer/contractor relationships, non-compete agreements, etc.) related to acquired businesses.

³ Income tax benefits (using a 39 percent marginal tax rate) from amortization for income tax purposes of indefinite-lived assets (Goodwill & Trademarks) on acquisitions that the Company obtained a full tax-basis step up in the assets acquired. For income tax purposes, these assets are amortized on a straight-line basis over 15 years. For financial reporting purposes, these assets are not amortized and a deferred tax provision is recorded that fully offsets the cash tax benefit in the determination of net income.

⁴ Income taxes (using a 39 percent marginal rate) on the portion of amortization of intangible assets that are non-deductible for income tax purposes (amortization related to CyberCoders, which is not deductible for tax purposes).